Incretin and glucagon-pathway research has become one of the most active areas of metabolic science, driven by a growing body of literature on how GLP-1, GIP and glucagon receptor signalling interact to regulate glucose handling, appetite and energy expenditure in laboratory models.
GLP-1: The Founding Incretin Pathway
Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from the gut in response to nutrient intake, and it has been studied extensively for its effects on insulin secretion, gastric emptying and appetite signalling in both cell-based and animal research models. GLP-1 receptor agonism is arguably the most thoroughly characterised pathway in this research area, and it has served as a reference point for evaluating newer multi-receptor research compounds.
GIP: A Second Incretin Signal
Glucose-dependent insulinotropic polypeptide (GIP) is a second incretin hormone, historically studied separately from GLP-1, but increasingly examined alongside it as research has explored whether combined GLP-1/GIP receptor engagement produces different effects in metabolic models than GLP-1 signalling alone. Compounds studied for dual GLP-1/GIP receptor activity represent one of the more active current research directions in this field.
Glucagon Receptor Research
Glucagon receptor signalling is mechanistically distinct from the incretin pathways — where GLP-1 and GIP are associated with insulin secretion, glucagon receptor activation is classically associated with hepatic glucose output and, in some research models, energy expenditure. Triple-pathway research compounds engaging GLP-1, GIP and glucagon receptors simultaneously represent a further, more recent research direction, reflecting interest in whether combining these mechanisms produces distinct metabolic research outcomes compared with single- or dual-pathway compounds.
Research Model Considerations
Metabolic pathway research in this area spans isolated cell and tissue assays, rodent models of metabolic dysfunction, and, for some compounds, human clinical research. Findings can differ meaningfully between model systems, and receptor engagement profiles vary between compounds within this class, making careful reference to a specific compound’s published receptor-binding and model data important when designing a research protocol.
Handling and Documentation
These compounds are generally supplied as lyophilized peptides and should be handled according to general peptide storage practice: cold-chain storage prior to reconstitution, and refrigerated, prompt use of reconstituted material, consistent with the guidance in our storage and stability overview.
Research Use Only. This overview is provided for general scientific education about metabolic pathway research. It does not describe or endorse any human or veterinary use, dosing or treatment.